Missouri jury sides with Enfamil maker Mead Johnson in case over preterm baby formula

A St. Louis jury rejected claims in favor of Mead Johnson, siding with the company in a case alleging its specialized preterm infant formula caused necrotizing enterocolitis (NEC), a disease with >20% mortality risk. The decision was the latest in ~1,000 similar lawsuits involving Mead Johnson (Enfamil) and Abbott (Similac); Mead Johnson said its specialized products do not cause NEC, while plaintiffs’ attorneys plan to evaluate options. Prior litigation already showed mixed outcomes, including an Illinois appeals court last month overturning a $60M Mead Johnson verdict due to jury instruction issues.

Analysis

This is incremental evidence that the defense can win on causation, which should shave some probability-weighted liability off ABT and JSVGF, but it does not eliminate the overhang because the centralized docket is still large and the verdict mix remains inconsistent. The market mechanism is mainly reserve risk and multiple compression, not a meaningful revenue hit: the neonatal hospital category is too small to matter to group earnings unless management eventually exits the line.

Second-order, the real commercial risk is procurement behavior. Even without liability findings, NICUs may keep de-risking the category by switching toward donor milk, alternate fortifiers, or suppliers with cleaner legal profiles, which would be a slow grind against the segment over 6-18 months. For ABT, the bigger watch item is whether legal noise starts to affect management willingness to maintain the franchise; for Reckitt/JSVGF, a string of defense outcomes would strengthen settlement leverage, but one plaintiff bellwether could quickly reprice that optimism.

Contrarian view: consensus may be overstating franchise damage and understating how little operating exposure there is relative to these companies' broader portfolios. The more durable risk is a slow rise in reserves and headline volatility over the next few quarters, which can cap multiples even if ultimate cash losses are manageable. F and TSLA have no material first-order readthrough here; any move would be noise, not a thesis.

Key Decisions for Investors

• No immediate trade: let the docket and reserve disclosures do the work; the verdict is supportive but not enough to justify a standalone position.
• Buy ABT on a 2-4% post-headline pullback only if upcoming commentary leaves litigation reserves unchanged; thesis breaks if management guides higher reserves or an Illinois bellwether swings back to plaintiffs.
• For JSVGF, use this as a tactical de-risking event if you were short into trial, but do not press a new short unless the next trial produces plaintiff momentum; upside is more about settlement leverage than operating acceleration.
• Ignore F and TSLA for this event; there is no credible cross-sector earnings or demand readthrough.